The analyst continued, “The actual reported US sales will also be important in understanding to what extend new discounts resulting from PBM contracts started to be applied this quarter and if additional discounting could be expected before the end of the year”. Evercore ISI reissued a “buy” rating on shares of Gilead Sciences in a research note on Monday.
Advertisement
There are 12 covering research analysts that have issued an anticipated price level where they predict the stock will reach within the next year. Piper Jaffray reiterated a “buy” rating on shares of Gilead Sciences in a report on Saturday. Analysts at Goldman Sachs raised their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the business a neutral rating in a research note on Monday, July 20th.
Wall Street analysts have a mean estimate for long-term growth of $15.42 on the stock.
Shares of Gilead Sciences (NASDAQ:GILD) opened at 110.54 on Monday. 15,067,591 shares of the company’s stock the of traded control Gilead Sciences has a 52-week low of $85.95 and a 52-week high of $123.37. The stock has a-50-day moving average of $117.16 and a-200-day moving average of $107.08.
Gilead Sciences (NASDAQ:GILD) last released its earnings data on Thursday, April 30th.
Gilead Sciences, Inc. (NASDAQ:GILD) is scheduled to report its second-quarter earnings after the bell on Tuesday and investors, first and foremost, will be looking for HepC revenues and guidance for potential sales in the rest of 2015 in context of competitive dynamics after AbbVie Inc (NYSE:ABBV)’s launch of Viekira-Pak in December. The company has missed consensus earnings estimates only once in the past eight quarters. The company is next slated to report quarterly earnings on or around 2015-07-28. Gilead Sciences Inc.is up 9.2% in the last 3-month period.
The organization also recently declared a quarterly dividend, that has been paid on Monday. This represents a $1.72 annualized dividend and a dividend yield of 1.52%. The ex-dividend date of this dividend was Friday, June 12th.
In other Gilead Sciences information, COO John F. Milligan offered 100,000 shares of Gilead Sciences stock in a trade that happened on Tuesday, July 7th. The total value of the transaction was worth $8,302,700. Also, Director John Francis Cogan sold 27,000 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were offered at an average price of $120.13, for a whole trade of $3,243,510.00. The disclosure for this sale can be found here.
Gilead Sciences, Inc. (NASDAQ:GILD), is a study-based biopharmaceutical company that discovers, develops and commercializes innovative medications.
Advertisement
Gilead’s HIV portfolio includes Truvada, Atripla, Stribild, Complera, and Emtriva. Thus, to make its drugs available to the majority of the population, the company announced a 46% gross-to-net adjustment for both Harvoni and Sovaldi, to secure coverage from other large PBMs. The increased revenue is likely to be driven primarily by the company’s blockbuster HCV drugs, HIV drugs, and other anti-viral products.
